Research programme: deubiquitinating enzyme inhibitors - FORMA Therapeutics/University of Oxford
Latest Information Update: 19 Oct 2022
At a glance
- Originator University of Oxford
- Developer FORMA Therapeutics; University of Oxford
- Class Neuroprotectants; Small molecules
- Mechanism of Action Deubiquitinating enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 28 Jun 2022 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 09 Jun 2018 FORMA Therapeutics and University of Oxford entered into a licensing agreement for the development and commercialisation of deubiquitinating enzyme inhibitors